You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePromazine
Accession NumberDB00420  (APRD00358)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States.
Structure
Thumb
Synonyms
10-(3-(Dimethylamino)propyl)phenothiazine
Frenil
N-(3-Dimethylaminopropyl)phenothiazine
N-Dimethylamino-1-methylethyl thiodiphenylamine
N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine
Promazin
Promazina
Promazina
Promazine
Promazinum
External Identifiers
  • A 145
  • RP 3276
  • Wy 1094
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Promazine HCl Inj 50mg/mlliquid50 mgintramuscular; intravenousAbbott Laboratories, Limited1981-12-312008-06-06Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CombelenNot Available
PrazinePliva
SparineNot Available
TalofenAbbott
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Promazine Hydrochloride
53-60-1
Thumb
  • InChI Key: JIVSXRLRGOICGA-UHFFFAOYSA-N
  • Monoisotopic Mass: 320.111397079
  • Average Mass: 320.88
DBSALT000147
Categories
UNIIO9M39HTM5W
CAS number58-40-2
WeightAverage: 284.419
Monoisotopic: 284.13471934
Chemical FormulaC17H20N2S
InChI KeyInChIKey=ZGUGWUXLJSTTMA-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
IUPAC Name
dimethyl[3-(10H-phenothiazin-10-yl)propyl]amine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationUsed as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.
PharmacodynamicsPromazine belongs to a group of medications known as the phenothiazine antipsychotics. It acts by blocking a variety of receptors in the brain, particularly dopamine receptors. Dopamine is involved in transmitting signals between brain cells. When there is an excess amount of dopamine in the brain it causes over-stimulation of dopamine receptors. These receptors normally act to modify behaviour and over-stimulation may result in psychotic illness. Promazine hydrochloride blocks these receptors and stops them becoming over-stimulated, thereby helping to control psychotic illness. Promazine has weak extrapyramidal and autonomic side effects which lead to its use in the elderly, for restless or psychotic patients. Its anti-psychotic effect is also weaker and it is not useful in general psychiatry.
Mechanism of actionPromazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine.
Related Articles
AbsorptionAbsorption may be erratic and peak plasma concentrations show large interindividual differences.
Volume of distributionNot Available
Protein binding94%
Metabolism

Hepatic, primarily to N-desmethylpromazine and promazine sulfoxide.

SubstrateEnzymesProduct
Promazine
Promazine 5-sulfoxideDetails
Promazine
N-DesmethylpromazineDetails
Promazine
Not Available
3-HydroxypromazineDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects include: extrapyramidal symptoms, drowsiness, weight gain, dry mouth, constipation, endocrine effects (such as gynaecomastia and menstrual disturbance), sensitivity to sunlight and haemolytic anaemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9718
Blood Brain Barrier+0.987
Caco-2 permeable+0.8813
P-glycoprotein substrateSubstrate0.7933
P-glycoprotein inhibitor IInhibitor0.6857
P-glycoprotein inhibitor IIInhibitor0.6352
Renal organic cation transporterInhibitor0.7561
CYP450 2C9 substrateNon-substrate0.7526
CYP450 2D6 substrateSubstrate0.9334
CYP450 3A4 substrateSubstrate0.5578
CYP450 1A2 substrateInhibitor0.8935
CYP450 2C9 inhibitorNon-inhibitor0.9483
CYP450 2D6 inhibitorInhibitor0.9622
CYP450 2C19 inhibitorNon-inhibitor0.798
CYP450 3A4 inhibitorNon-inhibitor0.9166
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6784
Ames testNon AMES toxic0.9176
CarcinogenicityNon-carcinogens0.9545
BiodegradationNot ready biodegradable0.9921
Rat acute toxicity2.9416 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9662
hERG inhibition (predictor II)Inhibitor0.7828
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wyeth ayerst laboratories
  • Watson laboratories inc
  • Baxter healthcare corp anesthesia critical care
  • Apothecon sub bristol myers squibb co
  • Apothecon inc div bristol myers squibb
  • Bristol myers squibb co
Packagers
Dosage forms
FormRouteStrength
Liquidintramuscular; intravenous50 mg
Prices
Unit descriptionCostUnit
Chlorpromazine 25 mg/ml amp8.04USD ml
Chlorpromazine 200 mg tablet1.05USD tablet
Chlorpromazine Hcl 25 mg/ml0.88USD ml
Chlorpromazine 100 mg tablet0.39USD tablet
Novo-Chlorpromazine 100 mg Tablet0.35USD tablet
Chlorpromazine 10 mg tablet0.32USD tablet
Chlorpromazine 50 mg tablet0.3USD tablet
Novo-Chlorpromazine 50 mg Tablet0.21USD tablet
Novo-Chlorpromazine 25 mg Tablet0.18USD tablet
Chlorpromazine 25 mg tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point203-210 °C at 3.00E-01 mm HgPhysProp
water solubility14.2 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.55HANSCH,C ET AL. (1995)
logS-4.3ADME Research, USCD
pKa9.36SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0207 mg/mLALOGPS
logP4.63ALOGPS
logP3.93ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity88.95 m3·mol-1ChemAxon
Polarizability32.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.05 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9430000000-708a7cbef8d61ce76846View in MoNA
References
Synthesis Reference

DrugSyn.org

US2519886
General References
  1. Cubala WJ, Jakuszkowiak-Wojten K, Burkiewicz A, Wronska A: Promazine in the treatment of delusional parasitosis. Psychiatr Danub. 2011 Jun;23(2):198-9. [PubMed:21685861 ]
External Links
ATC CodesN05AA03
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (75.4 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetaminePromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetaminePromazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Promazine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Promazine can be increased when it is combined with 5&#39;-Deoxy-5&#39;-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Promazine is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Promazine can be increased when it is combined with Abiraterone.
AcebutololPromazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Promazine is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Promazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Promazine.
adipiplonThe risk or severity of adverse effects can be increased when Promazine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Promazine is combined with Agomelatine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Promazine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Promazine is combined with Alfaxalone.
AlfentanilPromazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Promazine.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Promazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Promazine.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Promazine.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Promazine.
AlphacetylmethadolPromazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Promazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Promazine.
AlprenololPromazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmantadineAmantadine may increase the QTc-prolonging activities of Promazine.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Promazine.
AmiodaronePromazine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Promazine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Promazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Promazine.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Promazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Amobarbital.
AmodiaquineThe serum concentration of Promazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Promazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Promazine is combined with Amperozide.
AmphetaminePromazine may decrease the stimulatory activities of Amphetamine.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Promazine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Promazine.
AnagrelidePromazine may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Promazine.
ApomorphineApomorphine may increase the QTc-prolonging activities of Promazine.
AprepitantThe serum concentration of Promazine can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Promazine.
ArformoterolArformoterol may increase the QTc-prolonging activities of Promazine.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Promazine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Promazine.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Promazine.
ArmodafinilThe metabolism of Promazine can be decreased when combined with Armodafinil.
ArotinololPromazine may increase the hypotensive activities of Arotinolol.
Arsenic trioxidePromazine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherThe serum concentration of Promazine can be increased when it is combined with Artemether.
ArtemetherPromazine may increase the QTc-prolonging activities of Artemether.
ArtesunateThe serum concentration of Promazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Promazine is combined with Articaine.
AsenapinePromazine may increase the QTc-prolonging activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Promazine.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Promazine.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Promazine.
AtenololPromazine may increase the hypotensive activities of Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Promazine.
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Promazine.
AtovaquoneThe serum concentration of Promazine can be increased when it is combined with Atovaquone.
AzaperoneThe risk or severity of adverse effects can be increased when Promazine is combined with Azaperone.
AzelastinePromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Promazine.
AzithromycinPromazine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Promazine can be decreased when combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Promazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Barbital.
BedaquilinePromazine may increase the QTc-prolonging activities of Bedaquiline.
BefunololPromazine may increase the hypotensive activities of Befunolol.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Promazine.
BenzocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Benzocaine.
BenzphetaminePromazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Promazine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Promazine.
BepridilThe metabolism of Bepridil can be decreased when combined with Promazine.
BetaxololPromazine may increase the hypotensive activities of Betaxolol.
BevantololPromazine may increase the hypotensive activities of Bevantolol.
BexaroteneThe serum concentration of Promazine can be decreased when it is combined with Bexarotene.
BezitramidePromazine may increase the hypotensive activities of Bezitramide.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololPromazine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe metabolism of Promazine can be decreased when combined with Boceprevir.
BopindololPromazine may increase the hypotensive activities of Bopindolol.
BortezomibBortezomib may increase the QTc-prolonging activities of Promazine.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Promazine.
BosentanThe serum concentration of Promazine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Promazine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Promazine.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promazine.
BrimonidineThe risk or severity of adverse effects can be increased when Promazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Promazine.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Promazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Promazine.
BrotizolamThe risk or severity of adverse effects can be increased when Promazine is combined with Brotizolam.
BufuralolPromazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Promazine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Promazine.
BupranololPromazine may increase the hypotensive activities of Bupranolol.
BuprenorphinePromazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Promazine.
BupropionThe metabolism of Bupropion can be decreased when combined with Promazine.
BuserelinBuserelin may increase the QTc-prolonging activities of Promazine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Promazine.
BuspironeThe metabolism of Buspirone can be decreased when combined with Promazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Promazine.
ButacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Promazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Promazine is combined with Butethal.
ButorphanolPromazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Promazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Promazine.
CaffeineThe metabolism of Promazine can be decreased when combined with Caffeine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CapecitabineThe metabolism of Promazine can be decreased when combined with Capecitabine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Promazine.
CarbamazepineThe risk or severity of adverse effects can be increased when Promazine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Promazine is combined with Carbinoxamine.
CarfentanilPromazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Promazine.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Promazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Promazine is combined with Carisoprodol.
CarteololPromazine may increase the hypotensive activities of Carteolol.
CarvedilolPromazine may increase the hypotensive activities of Carvedilol.
CeliprololPromazine may increase the hypotensive activities of Celiprolol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Promazine.
CeritinibThe serum concentration of Promazine can be increased when it is combined with Ceritinib.
CeritinibPromazine may increase the QTc-prolonging activities of Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Promazine is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Promazine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Promazine is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Promazine can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Promazine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Promazine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Promazine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Promazine can be increased when it is combined with Chloroquine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Promazine.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Promazine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Promazine.
ChlorphenterminePromazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Promazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Promazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Promazine is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Promazine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Promazine.
CholecalciferolThe metabolism of Promazine can be decreased when combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Promazine.
CimetidineThe metabolism of Promazine can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Cinchocaine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Promazine.
CiprofloxacinPromazine may increase the QTc-prolonging activities of Ciprofloxacin.
CisapridePromazine may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Promazine.
CitalopramPromazine may increase the QTc-prolonging activities of Citalopram.
ClarithromycinPromazine may increase the QTc-prolonging activities of Clarithromycin.
ClemastineThe metabolism of Promazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Promazine is combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Promazine.
ClidiniumThe risk or severity of adverse effects can be increased when Promazine is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Promazine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Promazine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Promazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Clonazepam.
ClonidineThe metabolism of Clonidine can be decreased when combined with Promazine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Promazine.
ClorazepateThe risk or severity of adverse effects can be increased when Promazine is combined with Clorazepate.
ClotrimazoleThe metabolism of Promazine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Clozapine can be decreased when combined with Promazine.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Promazine.
CobicistatThe metabolism of Promazine can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Promazine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Promazine.
ConivaptanThe serum concentration of Promazine can be increased when it is combined with Conivaptan.
CrizotinibPromazine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Promazine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Promazine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Promazine.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Promazine.
CyclosporineThe metabolism of Promazine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Promazine can be decreased when it is combined with Cyproterone acetate.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Promazine.
DantroleneThe risk or severity of adverse effects can be increased when Promazine is combined with Dantrolene.
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Promazine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Promazine.
DapoxetineThe risk or severity of adverse effects can be increased when Promazine is combined with Dapoxetine.
DapsoneThe serum concentration of Promazine can be increased when it is combined with Dapsone.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Promazine.
DarunavirThe metabolism of Promazine can be decreased when combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Promazine.
DasatinibThe serum concentration of Promazine can be increased when it is combined with Dasatinib.
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Promazine.
DeferasiroxThe serum concentration of Promazine can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Promazine.
DelavirdineThe metabolism of Promazine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Promazine is combined with deramciclane.
DesfluraneDesflurane may increase the QTc-prolonging activities of Promazine.
DesfluraneThe risk or severity of adverse effects can be increased when Promazine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Promazine.
DesipramineThe metabolism of Desipramine can be decreased when combined with Promazine.
DesloratadineThe risk or severity of adverse effects can be increased when Promazine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Promazine.
DetomidineThe risk or severity of adverse effects can be increased when Promazine is combined with Detomidine.
DexamethasoneThe serum concentration of Promazine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Promazine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexmedetomidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Promazine.
DextroamphetaminePromazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Promazine.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Promazine.
DextromoramidePromazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Promazine.
DextropropoxyphenePromazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Promazine.
DezocinePromazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Promazine.
DiazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Promazine is combined with Difenoxin.
DihydrocodeinePromazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Promazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Promazine.
DihydroetorphinePromazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Promazine.
DihydromorphinePromazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Promazine.
DiltiazemThe metabolism of Promazine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Promazine is combined with Dimenhydrinate.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Promazine.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Promazine.
DiphenoxylatePromazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Promazine.
DisopyramidePromazine may increase the QTc-prolonging activities of Disopyramide.
DofetilidePromazine may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Promazine.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Promazine.
DomperidonePromazine may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Promazine.
DopamineThe metabolism of Dopamine can be decreased when combined with Promazine.
DoramectinThe risk or severity of adverse effects can be increased when Promazine is combined with Doramectin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Promazine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Promazine.
DoxepinThe metabolism of Doxepin can be decreased when combined with Promazine.
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Promazine.
DoxycyclineThe serum concentration of Promazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Promazine.
DoxylamineThe risk or severity of adverse effects can be increased when Promazine is combined with Doxylamine.
DPDPEPromazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Promazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Promazine.
DronedaronePromazine may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Promazine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Promazine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Promazine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Promazine.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Promazine.
DyclonineThe risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Promazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Promazine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Promazine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Promazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Promazine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Promazine.
EliglustatPromazine may increase the QTc-prolonging activities of Eliglustat.
EncainideThe metabolism of Encainide can be decreased when combined with Promazine.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Promazine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Promazine.
EntacaponeThe risk or severity of adverse effects can be increased when Promazine is combined with Entacapone.
EnzalutamideThe serum concentration of Promazine can be decreased when it is combined with Enzalutamide.
EpinastineThe metabolism of Epinastine can be decreased when combined with Promazine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Promazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Promazine.
EribulinEribulin may increase the QTc-prolonging activities of Promazine.
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Promazine.
ErythromycinPromazine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Promazine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Promazine.
EscitalopramPromazine may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Promazine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Promazine.
EsmololPromazine may increase the hypotensive activities of Esmolol.
EsomeprazoleThe metabolism of Promazine can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Promazine.
EthanolPromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Promazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promazine.
EthosuximideThe risk or severity of adverse effects can be increased when Promazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Promazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl loflazepate.
EthylmorphinePromazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Promazine.
EtidocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Promazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Promazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Promazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Promazine is combined with Etoperidone.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Promazine.
EtorphinePromazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Promazine.
EtravirineThe serum concentration of Promazine can be decreased when it is combined with Etravirine.
EzogabineEzogabine may increase the QTc-prolonging activities of Promazine.
EzogabineThe risk or severity of adverse effects can be increased when Promazine is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Promazine.
FelbamateFelbamate may increase the QTc-prolonging activities of Promazine.
FelbamateThe risk or severity of adverse effects can be increased when Promazine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Promazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Promazine is combined with Fenfluramine.
FentanylPromazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Promazine.
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Promazine.
FexofenadineThe risk or severity of adverse effects can be increased when Promazine is combined with Fexofenadine.
FingolimodFingolimod may increase the QTc-prolonging activities of Promazine.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Promazine.
FlecainideFlecainide may increase the QTc-prolonging activities of Promazine.
FlecainideThe metabolism of Flecainide can be decreased when combined with Promazine.
FlibanserinThe risk or severity of adverse effects can be increased when Promazine is combined with Flibanserin.
FloxuridineThe metabolism of Promazine can be decreased when combined with Floxuridine.
FluconazoleFluconazole may increase the QTc-prolonging activities of Promazine.
FludiazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Promazine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Promazine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Flunitrazepam.
FluorouracilThe metabolism of Promazine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Promazine.
FluoxetinePromazine may increase the QTc-prolonging activities of Fluoxetine.
FlupentixolPromazine may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Promazine.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Promazine.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Promazine.
FlurazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Promazine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Promazine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Promazine.
FluvoxamineThe risk or severity of adverse effects can be increased when Promazine is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Promazine.
FormoterolThe metabolism of Formoterol can be decreased when combined with Promazine.
FosamprenavirThe metabolism of Promazine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Promazine can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Promazine.
FosphenytoinThe risk or severity of adverse effects can be increased when Promazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Promazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Promazine.
Fusidic AcidThe serum concentration of Promazine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Promazine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Promazine is combined with gabapentin enacarbil.
Gadobenic acidPromazine may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Promazine.
GalantamineThe metabolism of Galantamine can be decreased when combined with Promazine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Promazine is combined with Gamma Hydroxybutyric Acid.
GefitinibThe metabolism of Gefitinib can be decreased when combined with Promazine.
GemfibrozilThe metabolism of Promazine can be decreased when combined with Gemfibrozil.
GemifloxacinPromazine may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Promazine is combined with Glutethimide.
GoserelinGoserelin may increase the QTc-prolonging activities of Promazine.
GranisetronGranisetron may increase the QTc-prolonging activities of Promazine.
GranisetronThe metabolism of Granisetron can be decreased when combined with Promazine.
GuanfacineThe risk or severity of adverse effects can be increased when Promazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Halazepam.
HalofantrineThe serum concentration of Promazine can be increased when it is combined with Halofantrine.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Promazine.
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Promazine.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Promazine.
HalothaneThe metabolism of Halothane can be decreased when combined with Promazine.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Promazine.
HeroinPromazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Promazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Promazine.
HydrocodonePromazine may increase the hypotensive activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Promazine.
HydromorphonePromazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Promazine.
Hydroxyamphetamine hydrobromidePromazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Promazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Promazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Promazine is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Promazine.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Promazine.
IbutilidePromazine may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Promazine.
IdelalisibThe serum concentration of Promazine can be increased when it is combined with Idelalisib.
IloperidonePromazine may increase the QTc-prolonging activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Promazine.
ImatinibThe metabolism of Promazine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Promazine.
ImipramineThe metabolism of Imipramine can be decreased when combined with Promazine.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Promazine.
IndalpineThe risk or severity of adverse effects can be increased when Promazine is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Promazine.
IndenololPromazine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Promazine can be decreased when combined with Indinavir.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Promazine.
IrbesartanThe metabolism of Promazine can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Promazine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Promazine.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Promazine.
IsofluraneThe risk or severity of adverse effects can be increased when Promazine is combined with Isoflurane.
IsoniazidThe metabolism of Promazine can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the QTc-prolonging activities of Promazine.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Promazine.
IvabradineIvabradine may increase the QTc-prolonging activities of Promazine.
IvacaftorThe serum concentration of Promazine can be increased when it is combined with Ivacaftor.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Promazine.
KetamineThe risk or severity of adverse effects can be increased when Promazine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Ketazolam.
KetobemidonePromazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Promazine.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Promazine.
LabetalolPromazine may increase the hypotensive activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Promazine is combined with Lamotrigine.
LapatinibLapatinib may increase the QTc-prolonging activities of Promazine.
LeflunomideThe metabolism of Promazine can be decreased when combined with Leflunomide.
LenvatinibPromazine may increase the QTc-prolonging activities of Lenvatinib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Promazine.
LevetiracetamThe risk or severity of adverse effects can be increased when Promazine is combined with Levetiracetam.
LevobunololPromazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Promazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Promazine is combined with Levocetirizine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Promazine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Promazine.
LevofloxacinPromazine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetatePromazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Promazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Promazine is combined with Levomilnacipran.
LevorphanolPromazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Promazine.
LidocaineThe metabolism of Promazine can be decreased when combined with Lidocaine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Promazine.
LisdexamfetaminePromazine may decrease the stimulatory activities of Lisdexamfetamine.
LisurideThe metabolism of Lisuride can be decreased when combined with Promazine.
LithiumLithium may increase the neurotoxic activities of Promazine.
LithiumThe risk or severity of adverse effects can be increased when Promazine is combined with Lithium.
LofentanilPromazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Promazine.
LomustineThe metabolism of Lomustine can be decreased when combined with Promazine.
LoperamideThe metabolism of Loperamide can be decreased when combined with Promazine.
LopinavirPromazine may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Promazine can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Promazine.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Promazine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Promazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Promazine.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Promazine.
LosartanThe metabolism of Promazine can be decreased when combined with Losartan.
LovastatinThe metabolism of Promazine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Promazine.
Lu AA21004The risk or severity of adverse effects can be increased when Promazine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Promazine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Promazine can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Promazine can be increased when it is combined with Lumefantrine.
LumefantrinePromazine may increase the QTc-prolonging activities of Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Promazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Promazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Promazine.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Promazine.
MeclizineThe risk or severity of adverse effects can be increased when Promazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Promazine is combined with Medetomidine.
MefloquineThe serum concentration of Promazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Promazine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Promazine is combined with Melperone.
MephenterminePromazine may decrease the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Promazine.
MepivacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promazine.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Promazine.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Promazine.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Promazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Promazine is combined with Metaxalone.
MethadonePromazine may increase the hypotensive activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Promazine.
Methadyl AcetatePromazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Promazine.
MethamphetaminePromazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Promazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Promazine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Promazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Promazine is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Promazine.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Promazine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Promazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Promazine.
MethsuximideThe risk or severity of adverse effects can be increased when Promazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenobarbital.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Promazine.
MetipranololPromazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promazine.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Promazine.
MetoprololPromazine may increase the hypotensive activities of Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Promazine.
MetyrosinePromazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Promazine.
MexiletineThe metabolism of Promazine can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Promazine.
MidazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Midazolam.
MifepristoneMifepristone may increase the QTc-prolonging activities of Promazine.
MilnacipranThe risk or severity of adverse effects can be increased when Promazine is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Promazine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promazine.
MirabegronMirabegron may increase the QTc-prolonging activities of Promazine.
MirabegronThe metabolism of Mirabegron can be decreased when combined with Promazine.
MirtazapinePromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Promazine.
MitotaneThe serum concentration of Promazine can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Promazine.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Promazine.
ModafinilThe serum concentration of Promazine can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Promazine.
MolindoneThe risk or severity of adverse effects can be increased when Promazine is combined with Molindone.
MorphinePromazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Promazine.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Promazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Promazine.
NabiloneThe risk or severity of adverse effects can be increased when Promazine is combined with Nabilone.
NadololPromazine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Promazine can be decreased when it is combined with Nafcillin.
NalbuphinePromazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Promazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Promazine.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Promazine.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Promazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Promazine.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Promazine.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Promazine.
NetupitantThe serum concentration of Promazine can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Promazine.
NevirapineThe metabolism of Promazine can be decreased when combined with Nevirapine.
NicardipineNicardipine may increase the QTc-prolonging activities of Promazine.
NicardipineThe metabolism of Nicardipine can be decreased when combined with Promazine.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Promazine.
NicotineThe metabolism of Nicotine can be decreased when combined with Promazine.
NifedipineThe metabolism of Nifedipine can be decreased when combined with Promazine.
NilotinibPromazine may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Promazine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Nitrazepam.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Promazine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Promazine is combined with Nitrous oxide.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Promazine.
NormethadonePromazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Promazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Promazine.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Promazine.
OctreotideOctreotide may increase the QTc-prolonging activities of Promazine.
OfloxacinPromazine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Promazine is combined with Olanzapine.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Promazine.
OlaparibThe metabolism of Promazine can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Promazine.
OlopatadineThe risk or severity of adverse effects can be increased when Promazine is combined with Olopatadine.
OmeprazoleThe metabolism of Promazine can be decreased when combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Promazine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Promazine.
OpiumPromazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Promazine.
OrphenadrinePromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Promazine.
OsanetantThe risk or severity of adverse effects can be increased when Promazine is combined with Osanetant.
OsimertinibThe serum concentration of Promazine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Oxazepam.
OxprenololPromazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Promazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Oxybuprocaine.
OxycodonePromazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Promazine.
OxymorphonePromazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Promazine.
OxytocinOxytocin may increase the QTc-prolonging activities of Promazine.
PalbociclibThe serum concentration of Promazine can be increased when it is combined with Palbociclib.
PaliperidonePromazine may increase the QTc-prolonging activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Promazine.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Promazine.
PanobinostatPromazine may increase the QTc-prolonging activities of Panobinostat.
PantoprazoleThe metabolism of Promazine can be decreased when combined with Pantoprazole.
ParaldehydePromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Promazine.
ParoxetineThe risk or severity of adverse effects can be increased when Promazine is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Promazine.
PazopanibPazopanib may increase the QTc-prolonging activities of Promazine.
PazopanibThe metabolism of Pazopanib can be decreased when combined with Promazine.
Peginterferon alfa-2bThe serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.
PenbutololPromazine may increase the hypotensive activities of Penbutolol.
PentamidinePentamidine may increase the QTc-prolonging activities of Promazine.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Promazine.
PentazocinePromazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Promazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Promazine.
PerampanelThe risk or severity of adverse effects can be increased when Promazine is combined with Perampanel.
PerflutrenPromazine may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Promazine.
PerospironeThe risk or severity of adverse effects can be increased when Promazine is combined with Perospirone.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Promazine.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Promazine.
PethidinePromazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Promazine.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Promazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promazine.
PhenforminThe metabolism of Phenformin can be decreased when combined with Promazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Promazine is combined with Phenoxyethanol.
PhenterminePromazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Promazine is combined with Phenytoin.
PimozidePromazine may increase the QTc-prolonging activities of Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Promazine.
PindololPromazine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Promazine is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Promazine.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Promazine.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Promazine.
PizotifenThe risk or severity of adverse effects can be increased when Promazine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Promazine is combined with Pomalidomide.
PonatinibThe metabolism of Ponatinib can be decreased when combined with Promazine.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Promazine.
PractololPromazine may increase the hypotensive activities of Practolol.
PramipexolePromazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Promazine.
PrilocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Prilocaine.
PrimaquineThe serum concentration of Promazine can be increased when it is combined with Primaquine.
PrimaquinePromazine may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Promazine is combined with Primidone.
ProcainamidePromazine may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Promazine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Promazine.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Promazine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Promazine.
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Promazine.
ProguanilThe serum concentration of Promazine can be increased when it is combined with Proguanil.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Promazine.
PromethazineThe metabolism of Promethazine can be decreased when combined with Promazine.
PropafenoneThe serum concentration of Promazine can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Promazine.
ProparacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Proparacaine.
PropofolPropofol may increase the QTc-prolonging activities of Promazine.
PropofolThe metabolism of Propofol can be decreased when combined with Promazine.
PropoxycaineThe risk or severity of adverse effects can be increased when Promazine is combined with Propoxycaine.
PropranololPromazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Promazine.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Promazine.
PSD502The risk or severity of adverse effects can be increased when Promazine is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Promazine.
PyrimethamineThe serum concentration of Promazine can be increased when it is combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Quazepam.
QuetiapinePromazine may increase the QTc-prolonging activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Promazine.
QuinacrineThe serum concentration of Promazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Promazine.
QuinidineThe serum concentration of Promazine can be increased when it is combined with Quinidine.
QuinidinePromazine may increase the QTc-prolonging activities of Quinidine.
QuinineThe serum concentration of Promazine can be increased when it is combined with Quinine.
QuininePromazine may increase the QTc-prolonging activities of Quinine.
RadicicolThe serum concentration of Promazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Promazine is combined with Ramelteon.
RanitidineThe metabolism of Ranitidine can be decreased when combined with Promazine.
RanolazineRanolazine may increase the QTc-prolonging activities of Promazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Promazine.
RemifentanilPromazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Promazine.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Promazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Promazine.
repinotanThe metabolism of repinotan can be decreased when combined with Promazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Promazine.
RifabutinThe metabolism of Promazine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Promazine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Promazine can be increased when combined with Rifapentine.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Promazine.
RisperidoneRisperidone may increase the QTc-prolonging activities of Promazine.
RisperidoneThe metabolism of Risperidone can be decreased when combined with Promazine.
RitonavirRitonavir may increase the QTc-prolonging activities of Promazine.
RitonavirThe metabolism of Ritonavir can be decreased when combined with Promazine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Promazine.
RomifidineThe risk or severity of adverse effects can be increased when Promazine is combined with Romifidine.
RopinirolePromazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Promazine can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Promazine.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Promazine.
RotigotinePromazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Promazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Promazine is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Promazine.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Promazine.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Promazine.
SaquinavirThe metabolism of Saquinavir can be decreased when combined with Promazine.
ScopolamineThe risk or severity of adverse effects can be increased when Promazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Promazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Promazine.
SertindoleThe metabolism of Sertindole can be decreased when combined with Promazine.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Promazine.
SertralineThe risk or severity of adverse effects can be increased when Promazine is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Promazine.
SevofluraneThe risk or severity of adverse effects can be increased when Promazine is combined with Sevoflurane.
SildenafilThe metabolism of Promazine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Promazine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Promazine can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Promazine.
SinefunginThe serum concentration of Promazine can be increased when it is combined with Sinefungin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Promazine is combined with Sodium oxybate.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Promazine.
SorafenibSorafenib may increase the QTc-prolonging activities of Promazine.
SotalolPromazine may increase the QTc-prolonging activities of Sotalol.
SparteineThe metabolism of Sparteine can be decreased when combined with Promazine.
St. John's WortThe serum concentration of Promazine can be decreased when it is combined with St. John&#39;s Wort.
StiripentolThe risk or severity of adverse effects can be increased when Promazine is combined with Stiripentol.
SufentanilPromazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Promazine.
SulfadiazineThe metabolism of Promazine can be decreased when combined with Sulfadiazine.
SulfadoxineThe serum concentration of Promazine can be increased when it is combined with Sulfadoxine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Promazine.
SulfametopyrazineThe serum concentration of Promazine can be increased when it is combined with Sulfametopyrazine.
SulfisoxazolePromazine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Promazine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Promazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Promazine.
SunitinibSunitinib may increase the QTc-prolonging activities of Promazine.
SuvorexantThe risk or severity of adverse effects can be increased when Promazine is combined with Suvorexant.
tafenoquineThe serum concentration of Promazine can be increased when it is combined with tafenoquine.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Promazine.
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Promazine.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Promazine.
TapentadolPromazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Promazine.
TasimelteonThe risk or severity of adverse effects can be increased when Promazine is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Promazine.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Promazine.
TelaprevirThe metabolism of Promazine can be decreased when combined with Telaprevir.
TelavancinPromazine may increase the QTc-prolonging activities of Telavancin.
TelithromycinPromazine may increase the QTc-prolonging activities of Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Promazine.
TenofovirThe metabolism of Promazine can be decreased when combined with Tenofovir.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Promazine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Promazine.
TeriflunomideThe serum concentration of Promazine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Promazine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Promazine.
TetrabenazinePromazine may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Promazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Promazine is combined with Tetrodotoxin.
ThalidomidePromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Promazine.
TheophyllineThe metabolism of Promazine can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Promazine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Promazine is combined with Thiopental.
ThioridazinePromazine may increase the QTc-prolonging activities of Thioridazine.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Promazine.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Promazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Promazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Promazine is combined with Tiagabine.
TicagrelorThe metabolism of Promazine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Promazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Promazine is combined with Tiletamine.
TimololPromazine may increase the hypotensive activities of Timolol.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Promazine.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Promazine.
TizanidineTizanidine may increase the QTc-prolonging activities of Promazine.
TizanidineThe risk or severity of adverse effects can be increased when Promazine is combined with Tizanidine.
TocilizumabThe serum concentration of Promazine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Promazine can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Promazine is combined with Tolcapone.
TolterodineTolterodine may increase the QTc-prolonging activities of Promazine.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Promazine.
TopiramateThe risk or severity of adverse effects can be increased when Promazine is combined with Topiramate.
ToremifenePromazine may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Promazine.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Promazine.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Promazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Promazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Promazine.
TrazodoneThe risk or severity of adverse effects can be increased when Promazine is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Promazine.
TriazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Promazine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triflupromazine.
TrimethoprimThe serum concentration of Promazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Promazine.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Promazine.
TriprolidineThe risk or severity of adverse effects can be increased when Promazine is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Promazine.
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Promazine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Promazine.
ValsartanThe metabolism of Promazine can be decreased when combined with Valsartan.
VandetanibPromazine may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Promazine.
VemurafenibThe serum concentration of Promazine can be increased when it is combined with Vemurafenib.
VemurafenibPromazine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Promazine.
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Promazine.
VerapamilThe metabolism of Promazine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Promazine is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Promazine.
VilazodoneThe risk or severity of adverse effects can be increased when Promazine is combined with Vilazodone.
VinblastineThe metabolism of Vinblastine can be decreased when combined with Promazine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Promazine.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Promazine.
VorinostatVorinostat may increase the QTc-prolonging activities of Promazine.
VortioxetineThe risk or severity of adverse effects can be increased when Promazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Promazine is combined with Xylazine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Promazine.
ZafirlukastThe metabolism of Promazine can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Promazine.
ZaleplonThe risk or severity of adverse effects can be increased when Promazine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Promazine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Promazine is combined with Zimelidine.
ZiprasidonePromazine may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Promazine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Promazine.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Promazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Promazine.
ZonisamideThe risk or severity of adverse effects can be increased when Promazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Promazine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Promazine is combined with Zotepine.
ZuclopenthixolPromazine may increase the QTc-prolonging activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Promazine.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Govitrapong P, Chagkutip J, Turakitwanakan W, Srikiatkhachorn A: Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment. Psychiatry Res. 2000 Sep 25;96(1):41-50. [PubMed:10980325 ]
  4. Govitrapong P, Mukda S, Turakitwanakan W, Dumrongphol H, Chindaduangratn C, Sanvarinda Y: Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Neurochem Int. 2002 Oct;41(4):209-16. [PubMed:12106771 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23